ArticleMolecular biotechnology2024
An In Silico Multi-epitopes Vaccine Ensemble and Characterization Against Nosocomial Proteus penneri.
Article in Molecular biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 44 citations in OpenAlex.
- Computational immunoinformatics and molecular modeling approaches for designing a multi-epitope vaccine against Babesia microti.BMC microbiology · 2026Article
- Identification and evaluation of tumor pyroptosis-associated antigens for design a vaccine candidate against lung cancer.Scientific reports · 2026Article
- Design of a global population-covering multi-epitope mRNA vaccine against Lassa virus using immunoinformatics.Scientific reports · 2026Article
- Immunoinformatic Design and Evaluation of a Multi-Epitope mRNA Vaccine RP14914P Targeting Latent Tuberculosis Infection.Pathogens (Basel, Switzerland) · 2026Article
- Bioinformatics and immunoinformatics approaches in the design of a multi-epitope vaccine targeting CTLA-4 for melanoma treatment.Molecular diversity · 2025Article
- Multi-epitope vaccine design against human metapneumovirus via reverse vaccinology and molecular modelling.Scientific reports · 2025Article
- Immunoinformatics investigation on pathogenic Escherichia coli proteome to develop an epitope-based peptide vaccine candidate.Molecular diversity · 2025Article
- Immunoinformatics-Based development of a Multi-Epitope vaccine candidate targeting coinfection by Klebsiella pneumoniae and Acinetobacter baumannii.BMC infectious diseases · 2025Article
- Design and evaluation of a multi-epitope subunit vaccine against human norovirus using an immunoinformatics approach.Osong public health and research perspectives · 2025Article
- Immunoinformatics based designing of a multi-epitope cancer vaccine targeting programmed cell death ligand 1.Scientific reports · 2025Article
- Designing a multi-epitope vaccine against Pseudomonas aeruginosa via integrating reverse vaccinology with immunoinformatics approaches.Scientific reports · 2025Article
- Molecular dynamics simulation shows enhanced stability in scaffold-based macromolecule, designed by protein engineering: a novel methodology adapted for converting Mtb Ag85A to a multi-epitope vaccine.Journal of molecular modeling · 2025Article
- Development of a novel multi-epitope subunit mRNA vaccine candidate to combat Acinetobacter baumannii.Scientific reports · 2025Article
- Article
- Targeting HIV-1 conserved regions: An immunoinformatic pathway to vaccine innovation for the Asia.PloS one · 2025Article
- Revolutionizing Chikungunya Vaccines: mRNA Breakthroughs With Molecular and Immune Simulations.Bioinformatics and biology insights · 2025Article
- In Silico Design and Characterization of a Multiepitope Vaccine Candidate AgainstJournal of immunology research · 2025Article
- Immunoinformatic strategy for developing multi-epitope subunit vaccine against Helicobacter pylori.PloS one · 2025Article
- Computational design of multi-epitope vaccine against Hepatitis C Virus infection using immunoinformatics techniques.PloS one · 2025Article
- Development of a broad-spectrum epitope-based vaccine against Streptococcus pneumoniae.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 5 countries.
Funding
Abstract
Proteus penneri (P. penneri) is a bacillus-shaped, gram-negative, facultative anaerobe bacterium that is primarily an invasive pathogen and the etiological agent of several hospital-associated infections. P. penneri strains are naturally resistant to macrolides, amoxicillin, oxacillin, penicillin G, and cephalosporins; in addition, no vaccines are available against these strains. This warrants efforts to propose a theoretical based multi-epitope vaccine construct to prevent pathogen infections. In this research, reverse vaccinology bioinformatics and immunoinformatics approaches were adopted for vaccine target identification and construction of a multi-epitope vaccine. In the first phase, a core proteome dataset of the targeted pathogen was obtained using the NCBI database and subjected to bacterial pan-genome analysis using bacterial pan-genome analysis (BPGA) to predict core protein sequences which were then used to find good vaccine target candidates. This identified two proteins, Hcp family type VI secretion system effector and superoxide dismutase family protein, as promising vaccine targets. Afterward using the IEDB database, different B-cell and T-cell epitopes were predicted. A set of four epitopes "KGSVNVQDRE, NTGKLTGTR, IIHSDSWNER, and KDGKPVPALK" were chosen for the development of a multi-epitope vaccine construct. A 183 amino acid long vaccine design was built along with "EAAAK" and "GPGPG" linkers and a cholera toxin B-subunit adjuvant. The designed vaccine model comprised immunodominant, non-toxic, non-allergenic, and physicochemical stable epitopes. The model vaccine was docked with MHC-I, MHC-II, and TLR-4 immune cell receptors using the Cluspro2.0 web server. The binding energy score of the vaccine was - 654.7 kcal/mol for MHC-I, - 738.4 kcal/mol for MHC-II, and - 695.0 kcal/mol for TLR-4. A molecular dynamic simulation was done using AMBER v20 package for dynamic behavior in nanoseconds. Additionally, MM-PBSA binding free energy analysis was done to test intermolecular binding interactions between docked molecules. The MM-GBSA net binding energy score was - 148.00 kcal/mol, - 118.00 kcal/mol, and - 127.00 kcal/mol for vaccine with TLR-4, MHC-I, and MHC-II, respectively. Overall, these in silico-based predictions indicated that the vaccine is highly promising in terms of developing protective immunity against P. penneri. However, additional experimental validation is required to unveil the real immune response to the designed vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.